Neutral impactResults
Dr Reddy's share price spurts 4% post Q2 earnings; analysts upgrade rating
Business Standard 1 hr ago·26 Oct 2026, 4:42 am
Analysts at Systematix Institutional Research and Elara Securities upgraded rating on Dr Reddy's Laboratories stock from 'Hold' to 'Buy' and 'Reduce' to 'Accumulate', respectively.
Affected stocks
Neutral1 stock
Bull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.
Key takeaways
- Concerns Dr. Reddy's Laboratories (DRREDDY).
- Category: Results.
Why it matters
A routine update for Dr. Reddy's Laboratories. Use the price and stock snapshot to gauge how the market is responding.
